文献速递慢阻肺肺栓塞与肺血管病

肺功能受损与慢阻肺增加心血管疾病风险:加拿大队列研究

Impaired Spirometry and COPD Increase the Risk of Cardiovascular Disease: A Canadian Cohort Study.
PubMed 文献 · Chest · 2023-03-04

该研究基于加拿大阻塞性肺疾病队列(CanCOLD),比较肺功能受损者与正常者心血管疾病(CVD)的患病率和发病率。结果显示,肺功能受损和慢阻肺患者CVD患病率及发病率显著增高,但将肺功能受损加入风险评分未改善CVD预测。

要点

  • 肺功能受损和慢阻肺患者CVD患病率显著高于肺功能正常者。
  • 慢阻肺患者CVD发病率显著增加,尤其GOLD≥2期。
  • 将肺功能受损加入PCE或FRS风险评分未改善CVD预测判别。

核心结论

  • 社区人群中肺功能受损者,尤其中度及以上慢阻肺和PRISm者,CVD患病率和发病率高于肺功能正常者。
  • 患有慢阻肺增加CVD发生风险。

研究设计与样本

  • 分析嵌入加拿大阻塞性肺疾病队列(CanCOLD),比较肺功能受损与正常组CVD患病率和6.3年发病率。
  • 使用逻辑回归和Cox模型调整协变量,并评估PCE和FRS加入肺功能受损后的判别能力。
  • 共纳入1561人,其中肺功能正常726人,肺功能受损835人(GOLD 1期408人,GOLD≥2期331人,PRISm 96人)。

主要发现

  • GOLD 1期和GOLD≥2期未诊断慢阻肺比例分别为84%和58%。

关键数值与推荐

  • CVD患病率在PRISm和GOLD≥2期参与者中显著更高,但GOLD 1期不显著。
  • CVD发病率差异在GOLD≥2期慢阻肺中显著更高,但GOLD 1期不显著。
  • 将肺功能受损加入PCE或FRS后,预测CVD的判别能力低且有限。

临床怎么用

  • 社区中肺功能受损者应关注CVD风险,尤其中度及以上慢阻肺和PRISm人群。
  • 现有CVD风险评分加入肺功能受损未显改善预测,暂不推荐用于常规风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Individuals with COPD and preserved ratio impaired spirometry (PRISm) findings in clinical settings have an increased risk of cardiovascular disease (CVD). RESEARCH QUESTION: Do individuals with mild to moderate or worse COPD and PRISm findings in community settings have a higher prevalence and incidence of CVD compared with individuals with normal spirometry findings? Can CVD risk scores be improved when impaired spirometry is added? STUDY DESIGN AND METHODS: The analysis was embedded in the Canadian Cohort Obstructive Lung Disease (CanCOLD). Prevalence of CVD (ischemic heart disease [IHD] and heart failure [HF]) and their incidence over 6.3 years were compared between groups with impaired and normal spirometry findings using logistic regression and Cox models, respectively, adjusting for covariables. Discrimination of the pooled cohort equations (PCE) and Framingham risk score (FRS) in predicting CVD were assessed with and without impaired spirometry. RESULTS: Participants (n = 1,561) included 726 people with normal spirometry findings and 835 people with impaired spirometry findings (COPD Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 1 disease, n = 408; GOLD stage ≥ 2, n = 331; PRISm findings, n = 96). Rates of undiagnosed COPD were 84% in GOLD stage 1 and 58% in GOLD stage ≥ 2 groups. Prevalence of CVD (IHD or HF) was significantly higher among individuals with impaired spirometry findings and COPD compared with those with normal spirometry findings, with ORs of 1.66 (95% CI, 1.13-2.43; P = .01∗) (∗ indicates statistical significane with P < .05) and 1.55 (95% CI, 1.04-2.31; P = .033∗), respectively. Prevalence of CVD was significantly higher in participants having PRISm findings and COPD GOLD stage ≥ 2, but not GOLD stage 1. CVD incidence was significantly higher, with hazard ratios of 2.07 (95% CI, 1.10-3.91; P = .024∗) for the impaired spirometry group and 2.09 (95% CI, 1.10-3.98; P = .024∗) for the COPD group compared to individuals with normal spirometry findings. The difference was significantly higher among individuals with COPD GOLD stage ≥ 2, but not GOLD stage 1. The discrimination for predicting CVD was low and limited when impaired spirometry findings were added to either risk score. INTERPRETATION: Individuals with impaired spirometry findings, especially those with moderate or worse COPD and PRISm findings, have increased comorbid CVD compared with their peers with normal spirometry findings, and having COPD increases the risk of CVD developing.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Krishnan S, Tan WC, Farias R, et al. Impaired Spirometry and COPD Increase the Risk of Cardiovascular Disease: A Canadian Cohort Study. Chest. 2023. PMID: 36871842. doi:10.1016/j.chest.2023.02.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。